Tectonic Therapeutic Inc/$TECX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tectonic Therapeutic Inc
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Ticker
$TECX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
51
ISIN
US8789721086
Website
TECX Metrics
BasicAdvanced
$370M
-
-$4.72
-
-
Price and volume
Market cap
$370M
52-week high
$27.04
52-week low
$13.70
Average daily volume
163K
Financial strength
Current ratio
22.92
Quick ratio
22.668
Long term debt to equity
0.094
Total debt to equity
0.874
Interest coverage (TTM)
-659.84%
Profitability
EBITDA (TTM)
-61.717
Management effectiveness
Return on assets (TTM)
-22.89%
Return on equity (TTM)
-41.59%
Valuation
Price to book
1.23
Price to tangible book (TTM)
1.23
Price to free cash flow (TTM)
-3.903
Free cash flow yield (TTM)
-25.62%
Free cash flow per share (TTM)
-507.28%
Growth
Earnings per share change (TTM)
-88.53%
Bulls say / Bears say
Tectonic Therapeutic's lead program, TX45, demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF), supporting its progression into Phase 2 trials. (StreetInsider)
The company maintains a strong cash position, with $306.2 million in cash and cash equivalents as of March 31, 2025, providing a financial runway into the fourth quarter of 2028, including through key Phase 1b and Phase 2 readouts for TX45. (Tectonic Therapeutic Q1 2025 Financial Results)
Tectonic Therapeutic has selected TX2100 as the development candidate for its second program targeting Hereditary Hemorrhagic Telangiectasia (HHT), a genetic bleeding disorder with no approved therapies, indicating a robust pipeline addressing unmet medical needs. (Nasdaq)
The company reported a net loss of $15.9 million for the first quarter of 2025, reflecting the high costs associated with ongoing research and development activities. (Tectonic Therapeutic Q1 2025 Financial Results)
Tectonic Therapeutic's reliance on third-party contract research organizations and manufacturing organizations introduces supply chain dependencies and potential risks that could impact development timelines. (SEC Filing)
The company's focus on early-stage clinical programs means that profitability is years away and heavily dependent on the success of clinical trials and regulatory approvals, which are inherently uncertain. (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TECX News
AllArticlesVideos
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
GlobeNewsWire·1 month ago
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewsWire·1 month ago
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tectonic Therapeutic Inc stock?
Tectonic Therapeutic Inc (TECX) has a market cap of $370M as of June 19, 2025.
What is the P/E ratio for Tectonic Therapeutic Inc stock?
The price to earnings (P/E) ratio for Tectonic Therapeutic Inc (TECX) stock is 0 as of June 19, 2025.
Does Tectonic Therapeutic Inc stock pay dividends?
No, Tectonic Therapeutic Inc (TECX) stock does not pay dividends to its shareholders as of June 19, 2025.
When is the next Tectonic Therapeutic Inc dividend payment date?
Tectonic Therapeutic Inc (TECX) stock does not pay dividends to its shareholders.
What is the beta indicator for Tectonic Therapeutic Inc?
Tectonic Therapeutic Inc (TECX) does not currently have a Beta indicator.